<DOC>
	<DOCNO>NCT00052494</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Imatinib mesylate may stop growth tumor cell block enzymes necessary growth . Combining one chemotherapy drug imatinib mesylate may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine cisplatin , irinotecan , imatinib mesylate treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Imatinib Mesylate Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose imatinib mesylate administer cisplatin irinotecan patient extensive stage small cell lung cancer . - Determine recommend phase II dose imatinib mesylate patient treat regimen . - Determine response rate , median duration response , progression-free survival , median survival , overall survival patient treat regimen . OUTLINE : This multicenter , dose-escalation study imatinib mesylate . Patients receive cisplatin IV 1 hour day 1 irinotecan IV 60 minute day 1 , 8 , 15 . Treatment repeat every 28 day maximum 4 course . Patients also receive oral imatinib mesylate daily continually one week prior , , chemotherapy absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos imatinib mesylate maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient treat recommended phase II dose ( one dose level MTD ) . PROJECTED ACCRUAL : A total 12-24 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm extensive stage small cell lung cancer Incurable amenable treatment chemotherapy ckit positive immunohistochemistry original biopsy metastatic site At least one unidimensionally measurable lesion &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan No prior radiotherapy target measurable lesion ( ) , unless document disease progression No known brain metastasis PATIENT CHARACTERISTICS : Age Not specify Performance status ECOG 01 OR Karnofsky 70100 % Life expectancy More 6 week Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal AST and/or ALT ≤ 2.5 time upper limit normal Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Gastrointestinal No concurrent untreated upper gastrointestinal bleeding fully investigate No gastrointestinal disease would impair drug absorption Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception prior , , 3 month study participation No history ototoxicity No history peripheral neuropathy No traumatic injury within past 21 day No ongoing active infection No concurrent significant medical condition would preclude study participation No concurrent psychiatric condition social situation would preclude study compliance No malignancy within past 5 year except treated nonmelanoma skin cancer , carcinoma situ , stage A prostate cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No prior chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy No prior radiotherapy 25 % marrow Surgery More 3 week since prior major surgery No prior surgical procedure impair absorption Other No prior ckittargeted therapy No concurrent therapeutic dose warfarin Minidose warfarin prophylaxis lowmolecular weight heparin allow No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent amifostine No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>